Skip to Content

Publications Search - Abstract View

Title: Urinary estrogen metabolites and prostate cancer risk: a pilot study.
Authors: Kosti O,  Xu X,  Veenstra TD,  Hsing AW,  Chu LW,  Goldman L,  Bebu I,  Collins S,  Dritschilo A,  Lynch JH,  Goldman R
Journal: Prostate
Date: 2011 Apr
Branches: IIB
PubMed ID: 20886539
PMC ID: PMC3037420
Abstract: BACKGROUND: The high incidence of and few identified risk factors for prostate cancer underscore the need to further evaluate markers of prostate carcinogenesis. The aim of this pilot study was to evaluate urinary estrogen metabolites as a biomarker of prostate cancer risk. METHODS: Using a liquid chromatography-tandem mass spectrometry method, urinary concentrations of 15 estrogen metabolites were determined in 77 prostate cancer cases, 77 healthy controls, and 37 subjects who had no evidence of prostate cancer after a prostate biopsy. RESULTS: We observed an inverse association between the urinary 16-ketoestradiol (16-KE2) and 17-epiestriol (17-epiE3)--metabolites with high estrogenic activity--and prostate cancer risk. Men in the lowest quartile of 16-KE2, had a 4.6-fold risk of prostate cancer (OR=4.62, 95% CI=1.34-15.99), compared with those in the highest quartile. CONCLUSIONS: We observed modest differences in estrogen metabolite concentrations between prostate cancer patients and subjects without cancer. Larger studies with both androgen and estrogen measurements are needed to confirm these results to clarify further whether estrogen metabolites are independent biomarkers for prostate cancer risk and whether androgen/estrogen imbalance influences prostate cancer risk.